BR112016030172A2 - aptâmeros específicos para tlr-4 e usos dos mesmos - Google Patents
aptâmeros específicos para tlr-4 e usos dos mesmosInfo
- Publication number
- BR112016030172A2 BR112016030172A2 BR112016030172A BR112016030172A BR112016030172A2 BR 112016030172 A2 BR112016030172 A2 BR 112016030172A2 BR 112016030172 A BR112016030172 A BR 112016030172A BR 112016030172 A BR112016030172 A BR 112016030172A BR 112016030172 A2 BR112016030172 A2 BR 112016030172A2
- Authority
- BR
- Brazil
- Prior art keywords
- tlr
- relates
- aptamer
- methods
- increase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
Abstract
a presente invenção refere-se a um aptâmero de ácido nucleico com a capacidade de se ligar especificamente a e inibir tlr-4, a um complexo que compreende o dito aptâmero e um grupo funcional, assim como a composições farmacêuticas dos mesmos. a invenção também se refere a usos e métodos para detectar tlr-4 e a usos e métodos para inibir tlr-4. finalmente, a invenção também se refere a um aptâmero para uso na fabricação de um fármaco para o tratamento de uma patologia distinguida por um aumento na expressão de tlr4 e/ou um aumento na ativação de tlr-4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP201430955 | 2014-06-24 | ||
ES201430955A ES2555160B1 (es) | 2014-06-24 | 2014-06-24 | Aptámeros específicos de TLR-4 y usos de los mismos |
PCT/EP2015/064277 WO2015197706A1 (en) | 2014-06-24 | 2015-06-24 | Aptamers specific for tlr-4 and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016030172A2 true BR112016030172A2 (pt) | 2017-11-14 |
BR112016030172B1 BR112016030172B1 (pt) | 2022-11-01 |
Family
ID=53496661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016030172-2A BR112016030172B1 (pt) | 2014-06-24 | 2015-06-24 | Aptâmeros específicos para tlr-4 e usos dos mesmos |
Country Status (18)
Country | Link |
---|---|
US (4) | US10196642B2 (pt) |
EP (1) | EP3161139B1 (pt) |
JP (2) | JP6959738B2 (pt) |
KR (1) | KR102454682B1 (pt) |
CN (2) | CN106459980B (pt) |
AU (1) | AU2015279248B2 (pt) |
BR (1) | BR112016030172B1 (pt) |
CA (1) | CA2953020C (pt) |
DK (1) | DK3161139T3 (pt) |
ES (2) | ES2555160B1 (pt) |
MA (1) | MA40283A (pt) |
MX (1) | MX2016016992A (pt) |
PL (1) | PL3161139T3 (pt) |
PT (1) | PT3161139T (pt) |
RU (1) | RU2709718C9 (pt) |
SI (1) | SI3161139T1 (pt) |
WO (1) | WO2015197706A1 (pt) |
ZA (1) | ZA201700363B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3129462A1 (en) * | 2014-04-07 | 2017-02-15 | INSERM - Institut National de la Santé et de la Recherche Médicale | New method for producing outer membrane vesicles |
ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
EP3494994A1 (en) * | 2017-12-07 | 2019-06-12 | Universität zu Köln | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
CN113423833A (zh) * | 2018-09-28 | 2021-09-21 | 奥曼尼提纳米有限公司 | 用于选择功能性适体的方法和组合物 |
CN112805294A (zh) | 2018-09-28 | 2021-05-14 | 胡桃钳医疗公司 | 用于核酸递送的叔氨基脂化的阳离子肽 |
CA3114763A1 (en) | 2018-10-02 | 2020-04-09 | WearOptimo Pty Ltd | System for performing measurements on a biological subject |
WO2020230109A1 (en) * | 2019-05-16 | 2020-11-19 | Aptatargets, S.L. | Treatment of tlr-4 mediated diseases and conditions with aptamers targeting tlr-4 |
CN111474336B (zh) * | 2020-03-21 | 2023-07-28 | 南昌大学 | 一种铁氰化镍纳米粒化学发光适体传感器的制备方法及基于其检测8-OhdG的方法 |
US20230372407A1 (en) * | 2020-06-15 | 2023-11-23 | President And Fellows Of Harvard College | Methods for modulating tlr4 signaling |
CN114152599B (zh) * | 2021-12-01 | 2023-10-13 | 中国农业大学 | 一种基于双劈裂功能核酸变构的孔雀石绿生物传感器 |
WO2024146930A1 (en) | 2023-01-05 | 2024-07-11 | Aptatargets, S.L. | Aptoll molecules for the treatment of ischemic stroke and intracranial hemorrhages |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
EP1252335A4 (en) * | 2000-02-03 | 2005-03-02 | Res Dev Foundation | SIGNAL-TREATING APTAMERS THAT TRANSMIT MOLECULAR DETECTION TO A DIFFERENTIAL SIGNAL |
CN101227922A (zh) * | 2005-05-06 | 2008-07-23 | 斯克里普斯研究学院 | 经由CD14和Toll样受体4信号传导途径调节细胞的组合物和方法 |
US20060257411A1 (en) * | 2005-05-06 | 2006-11-16 | Bruce Beutler | Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway |
US20100015125A1 (en) * | 2005-06-17 | 2010-01-21 | University Of Rochester | Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion |
FR2892730A1 (fr) * | 2005-10-28 | 2007-05-04 | Biomerieux Sa | Methode pour detecter la presence ou le risque de developper un cancer |
US20090317802A1 (en) * | 2005-12-09 | 2009-12-24 | Bhatia Sangeeta N | Compositions and Methods to Monitor RNA Delivery to Cells |
WO2008076804A2 (en) * | 2006-12-13 | 2008-06-26 | Case Western Reserve University | Method of treating intrauterine inflammation |
KR20110081337A (ko) * | 2008-11-04 | 2011-07-13 | 이데라 파마슈티칼즈, 인코포레이티드 | 안티센스 올리고누클레오티드에 의한 toll―유사 수용체 4 발현의 조절 |
WO2010060030A1 (en) | 2008-11-24 | 2010-05-27 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | Tlr ligand-nucleic acid nanostructure as a novel immune modulatory agent and method of using the same |
EP2681314B1 (en) * | 2011-03-03 | 2017-11-01 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
CN103562387A (zh) * | 2011-03-03 | 2014-02-05 | 夸克医药公司 | Toll样受体途径的寡核苷酸调剂 |
ES2555160B1 (es) * | 2014-06-24 | 2016-10-25 | Aptus Biotech, S.L. | Aptámeros específicos de TLR-4 y usos de los mismos |
-
2014
- 2014-06-24 ES ES201430955A patent/ES2555160B1/es not_active Expired - Fee Related
-
2015
- 2015-06-24 BR BR112016030172-2A patent/BR112016030172B1/pt active IP Right Grant
- 2015-06-24 DK DK15732619.0T patent/DK3161139T3/da active
- 2015-06-24 WO PCT/EP2015/064277 patent/WO2015197706A1/en active Application Filing
- 2015-06-24 CN CN201580034070.1A patent/CN106459980B/zh active Active
- 2015-06-24 PT PT157326190T patent/PT3161139T/pt unknown
- 2015-06-24 PL PL15732619T patent/PL3161139T3/pl unknown
- 2015-06-24 JP JP2016575345A patent/JP6959738B2/ja active Active
- 2015-06-24 KR KR1020177001493A patent/KR102454682B1/ko active IP Right Grant
- 2015-06-24 SI SI201531392T patent/SI3161139T1/sl unknown
- 2015-06-24 US US15/322,021 patent/US10196642B2/en active Active
- 2015-06-24 MX MX2016016992A patent/MX2016016992A/es unknown
- 2015-06-24 ES ES15732619T patent/ES2825106T3/es active Active
- 2015-06-24 AU AU2015279248A patent/AU2015279248B2/en active Active
- 2015-06-24 CA CA2953020A patent/CA2953020C/en active Active
- 2015-06-24 EP EP15732619.0A patent/EP3161139B1/en active Active
- 2015-06-24 MA MA040283A patent/MA40283A/fr unknown
- 2015-06-24 CN CN202010953057.9A patent/CN112111495A/zh active Pending
- 2015-06-24 RU RU2016152094A patent/RU2709718C9/ru active
-
2017
- 2017-01-17 ZA ZA2017/00363A patent/ZA201700363B/en unknown
-
2018
- 2018-12-14 US US16/220,726 patent/US10808252B2/en active Active
-
2020
- 2020-05-07 JP JP2020082070A patent/JP2020127422A/ja active Pending
- 2020-09-16 US US17/022,984 patent/US11591603B2/en active Active
-
2023
- 2023-01-19 US US18/156,936 patent/US20230279402A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016030172A2 (pt) | aptâmeros específicos para tlr-4 e usos dos mesmos | |
CO2017011851A2 (es) | Compuestos novedosos | |
CY1121793T1 (el) | Εκλεκτικοι αναστολεις pi3k δελτα | |
BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
BR112016024644A2 (pt) | vacinas de ácido nucleico | |
BR112016022553A2 (pt) | Compostos e métodos para entrega transmembrana de moléculas? | |
UY35210A (es) | Inhibidores de autotaxina | |
BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
BR112015019909A2 (pt) | Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit | |
CO6551721A2 (es) | Moduladores de cinasa novedosos | |
BR112013027774A2 (pt) | novos compostos como moduladores de proteína quinases | |
BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
BR112015030385A2 (pt) | inibidores de pi3 delta e gama quinase seletivos duplos | |
BR112017004056A2 (pt) | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo | |
BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
CL2014002661A1 (es) | Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer. | |
BR112016021648A2 (pt) | novos compostos | |
GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
BR112015023523B8 (pt) | Composições farmacêuticas e recipiente de forma de dosagem única | |
BR112013001296A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa | |
BR112017006552A2 (pt) | composições e métodos para inibir a atividade biológica de biomoléculas solúveis | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: APTATARGETS, S.L. (ES) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2015, OBSERVADAS AS CONDICOES LEGAIS |